BioSpace News Archive

CAQH has launched CAQH ProView for Groups, simplifying the way data is shared between delegated provider groups and health plans

Technavio analysts forecast the global medical crutches market to grow at a CAGR of over 5% during the forecast period, according to their latest market research report.

ProSource360 announced today it is joining Cerner, a global leader in health care technology, and other industry leaders and innovators to help make seamless care available to the nation’s veterans.

Atlantic Health System, an integrated health care delivery system, today announced a partnership with theTranslational Genomics Research Institute (TGen)(TGen), an affiliate of City of Hope, and Origin Commercial Ventures to create a new platform to deliver economically viable immunotherapies and other breakthrough cancer treatments to the region through expedited access and novel payment options.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Food and Drug Administration (FDA) has approved Hemlibra® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors.

Richmond Vascular Center, Central Virginia’s state-of-the-art treatment center for Radiology Associates of Richmond and Surgical Associates of Richmond, is the first US site to offer the Ellipsys® Vascular Access System, a game-changing innovation for patients with End-Stage Renal Disease (ESRD).

An inventor from Raytown, Mo., wanted to fulfill the need for a customizable modular heat and cold therapy device.

BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, congratulates James Allison, Ph.D., for receiving the 2018 Nobel Prize in Physiology or Medicine recognizing his leading role in launching an effective new way to attack cancer by treating the immune system.

After having successfully treated 14 patients, a team of researchers at Université Laval’s Research Centre: The Tissue Engineering Laboratory (LOEX), led by professors at Université Laval and researchers at the CHU de Québec-Université Laval Research Centre, François A. Auger, Lucie Germain and Véronique Moulin, has just published their results pertaining to a new technique for burn patient treatment in the European Cells and Materials (eCM) Journal.

Griffin-American Healthcare REIT III, Inc. announced today that its board of directors has approved an updated estimated per share net asset value (“NAV”) of its common stock of $9.37 calculated as of June 30, 2018.